Quote:

---

Question: Are you satisfied with our current understanding of our MOA re: turning "cold" tumors "hot?" Or do you think there's 10% - 20% that we still have to learn?

---

As far as turning cold tumors hot that would have been obvious before any cancer trial. Leronlimab's turning from predominately M2 to M1 macrophages would ensure that. The puzzle is with PD-L1 expression. With M2 macrophages predominate it would make sense that there would be very low PD-L1 expression and an onslaught of M1 macrophages would increase that in response. But does PD-L1 go back down after that 90 days in response to CCL5 blockade?

As far as overall MOA in cancer we have 110% to learn. With the broad array of things that leronlimab affects it might take a 1,000 panel of proteins tests to get a very deep understanding. Then you'd have to figure out all the interactions.